← All trials
NCT07246252
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2024
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 2, 2024
- First posted
- Nov 24, 2025
- Last posted
- Nov 24, 2025
- Enrollment
- 114
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taizhou Mabtech Pharmaceutical Co., Ltd.Lead sponsor
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.